Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Luis A. López-Fernández"'
Autor:
Paula Zapata-Cobo, Sara Salvador-Matín, Marta Velasco, Laura M. Palomino, Susana Clemente, Oscar Segarra, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Montse Montraveta, Cesar Sánchez, Mar Tolín, Inés Loverdos, María José Fobelo, Victor Manuel Navas-López, Lorena Magallares, Ruth García-Romero, José Germán Sánchez-Hernández, Alejandro Rodríguez, Ferrán Bossacoma, María Jesús Balboa, Enrique Salcedo, María Sanjurjo-Sáez, Luis A. López-Fernández
Publikováno v:
Pharmacological Research, Vol 196, Iss , Pp 106938- (2023)
Externí odkaz:
https://doaj.org/article/29237a28c7fb4acf97d7fc04e6eb47d0
Autor:
Paula Zapata-Cobo, Sara Salvador-Martín, Marta Velasco, Laura M. Palomino, Susana Clemente, Oscar Segarra, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Montserrat Montraveta, Cesar Sánchez, Mar Tolín, Inés Loverdos, María Jesús Fobelo, Victor Manuel Navas-López, Lorena Magallares, Ruth García-Romero, José Germán Sánchez-Hernández, Alejandro Rodríguez, Ferrán Bossacoma, María Jesús Balboa, Enrique Salcedo, María Sanjurjo-Sáez, Luis A. López-Fernández
Publikováno v:
Pharmacological Research, Vol 194, Iss , Pp 106859- (2023)
Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate g
Externí odkaz:
https://doaj.org/article/932b1c7582b3485494608f6bff4859d4
Autor:
Paula Soria-Chacartegui, Gonzalo Villapalos-García, Luis A. López-Fernández, Marcos Navares-Gómez, Gina Mejía-Abril, Francisco Abad-Santos, Pablo Zubiaur
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2036 (2021)
Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity. Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD function, the main enzyme responsible for the metabolism of fluoropyrimidines. This
Externí odkaz:
https://doaj.org/article/e8ac976655a34f4bbe8c9cf51e102763
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
Publikováno v:
Pharmaceutics, Vol 13, Iss 11, p 1786 (2021)
The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psych
Externí odkaz:
https://doaj.org/article/b275a7c3d7d14dff9e7bd172375fb3fe
Autor:
Sara Salvador-Martín, Bartosz Kaczmarczyk, Rebeca Álvarez, Víctor Manuel Navas-López, Carmen Gallego-Fernández, Ana Moreno-Álvarez, Alfonso Solar-Boga, Cesar Sánchez, Mar Tolin, Marta Velasco, Rosana Muñoz-Codoceo, Alejandro Rodriguez-Martinez, Concepción A. Vayo, Ferrán Bossacoma, Gemma Pujol-Muncunill, María J. Fobelo, Antonio Millán-Jiménez, Lorena Magallares, Eva Martínez-Ojinaga, Inés Loverdos, Francisco J. Eizaguirre, José A. Blanca-García, Susana Clemente, Ruth García-Romero, Vicente Merino-Bohórquez, Rafael González de Caldas, Enrique Vázquez, Ana Dopazo, María Sanjurjo-Sáez, Luis A. López-Fernández
Publikováno v:
Pharmaceutics, Vol 13, Iss 1, p 77 (2021)
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF d
Externí odkaz:
https://doaj.org/article/c7b5825a40164690902dde36eb3bffe4
Autor:
Luis A. López-Fernández, Ana Delgado
Publikováno v:
Gaceta Sanitaria, Vol 18, Pp 112-117 (2004)
En este artículo se analizan las relaciones entre el sexo de los pacientes y los profesionales, la clase social y el tipo de aseguramiento, por un lado, y la práctica médica y la satisfacción con la atención recibida por otro. Cuando la atenció
Externí odkaz:
https://doaj.org/article/b095d51ccacb4a04a6448359f3300c99
Autor:
Sergio Gil-Manso, Iria Miguens Blanco, Bruce Motyka, Anne Halpin, Rocío López-Esteban, Verónica Astrid Pérez-Fernández, Diego Carbonell, Luis Andrés López-Fernández, Lori West, Rafael Correa-Rocha, Marjorie Pion
Publikováno v:
Virulence, Vol 13, Iss 1, Pp 30-45 (2022)
Since December 2019, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world. To eradicate it, it is crucial to acquire a strong and long-lasting anti-SARS-C
Externí odkaz:
https://doaj.org/article/b17bcd959ecb4f6fa0fb241230ed95e5
Autor:
Sergio Gil-Manso, Iria Miguens Blanco, Rocío López-Esteban, Diego Carbonell, Luis Andrés López-Fernández, Lori West, Rafael Correa-Rocha, Marjorie Pion
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
SARS-CoV-2 has infected more than 200 million people worldwide, with more than 4 million associated deaths. Although more than 80% of infected people develop asymptomatic or mild COVID-19, SARS-CoV-2 can induce a profound dysregulation of the immune
Externí odkaz:
https://doaj.org/article/3be06fe1db8f47b9ba42fad576df7b7e
Autor:
Adrián Bravo-Gómez, Sara Salvador-Martín, Paula Zapata-Cobo, María Sanjurjo-Sáez, Luis Andrés López-Fernández
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2082 (2022)
Background: The variant rs34983651 (UGT1A1*28) and its genotyping are used to prevent irinotecan-induced toxicity. Several variants are in close linkage disequilibrium. Our objective was to evaluate the potential correlation of genotyping UGT1A1*80 i
Externí odkaz:
https://doaj.org/article/d542b7b4cd3e4c1cb5b4118ff6dbcb98
Publikováno v:
Gaceta Sanitaria, Vol 36, Iss 1, Pp 94-95 (2022)
Externí odkaz:
https://doaj.org/article/454c21d6c9744e36b08829d84e7e4247